|Publication number||US5260301 A|
|Application number||US 07/984,239|
|Publication date||Nov 9, 1993|
|Filing date||Dec 1, 1992|
|Priority date||Mar 1, 1990|
|Publication number||07984239, 984239, US 5260301 A, US 5260301A, US-A-5260301, US5260301 A, US5260301A|
|Inventors||Shigeo Nakanishi, Iwao Yamanaka|
|Original Assignee||Fujisawa Pharmaceutical Co., Ltd.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (7), Referenced by (32), Classifications (34), Legal Events (6)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation of application Ser. No. 07/662,443, filed on Feb. 28, 1991, now abandoned.
The present invention relates to a pharmaceutical solution which contains the compound (I) or a pharmaceutically acceptable salt thereof described later that is known as showing immunosuppressive activity.
In detail, the present invention relates to the solution which shows long term storage stability in a nonaqeuous solution and may be diluted with such as physiological saline, glucose solution for injection, water, fruit juice, and the like without occurence of any precipitations of the compound(I).
Accordingly, the present invention relates to the above pharmaceutical solution which can be applied for various form of medicine such as intravenous injection, oral administrating liquidous medicine, or the like.
The compound(I) used in the present invention is shown as follows. ##STR2## wherein each vicinal pair of substituents [R1 and R2 ], [R3 and R4 ], [R5 and R6 ]independently
a) represent two vicinal hydrogen atoms, or
b) form a second bond between the vicinal carbon atoms to which they are attached;
in addition to its significance above, R2 may represent an alkyl group;
R7 represents H, OH, protected hydroxy or O-alkyl, or in conjunction with R1 it may represent ═O;
R8 and R9 independently represent H or OH;
R10 represents H, alkyl, alkyl substituted by one or more hydroxyl groups, alkenyl, alkenyl substituted by one or more hydroxyl groups, or alkyl substituted by =O;
X represents O (H,OH), (H,H) or --CH2 O--;
Y represents O, (H,OH), (H,H) or N--NR11 R12 or N--OR13 ;
R11 and R12 independently represent H, alkyl, aryl or tosyl;
R13, R14, R16, R17, R18, R19, R22 and R23 independently represent H or alkyl;
R20 and R21 independently represent O, or they may independently represent (R20 a, H) and (R21 a, H) respectively; R20 a and R21 a independently represent OH, O-alkyl or OCH2 OCH2 CH2 OCH3 or R21 a is protected hydroxy;
in addition, R20 a and R21 a may together represent an oxygen atoms in an epoxide ring;
n is 1, 2 or 3;
in addition to their significances above, Y, R10 and R23, together with the carbon atoms to which they are attached, may represent a 5- or 6- membered N-, S- or O-containing heterocyclic ring, which may be saturated or unsaturated, and which may be substistuted by one or more groups selected from alkyl, hydroxy, alkyl substituted by one or more hydroxyl groups, O-alkyl, benzyl and --CH2 Se(C6 H5).
The compound (I) and its pharmaceutically acceptable salt have remarkable immunosuppressive, antimicrobial and other pharmacologic activities and are known to be of value in the treatment and prevention of resistance to organ or tissue transplantation, graft-versus-host disease, various autoimmune disease and infectious disease (Japanese Kokai Patent Publication No. 61-148181/1986 and European Patent Publication No.0323042).
Such compound(I) and its pharmaceutically acceptable salt are prepared in the same manner as the one described in the above-mentioned two patent applications. Particularly, the macrolides, which are produced by fermentation of Streptmyces tsukubaensis No.9993 (FERM BP-927) or Streptmyces hygroscopicus subsp. yakushimaensis No.7238 (FERM BP-928), are numbered FR-900506, FR-900520, FR-900523 and FR-900525.
It is considered to prepare various kind forms of medicine such as powder, suspension, pharmaceutical solution which contains the compound (I) and pharmaceutically acceptable salt thereof (hereinafter the term "compound (I)" is representatively used to show them). However it is difficult to prepare stable pharmaceutical solution of the compound(I), which causes a difficulty in applying the compound (I) for clinical use where it is desired to prepare pharmaceutical solution e.g., injection, oral administrating liquid, local scattering solution, dropping lotion in the eye, and the like.
It is the object of the present invention to prepare pharmaceutical solution containing the compound (I).
In more detail it is the object of the present invention to prepare the above pharmaceutical solution which shows clear aqueous solution state that is especially desired for intravenous injection.
Pharmaceutical solution of the present invention comprises of the above compound (I) as an active ingredient, a pharmaceutically acceptable surface active agent and nonaqueous solvent.
In the above and subsequent descriptions on the present invention, suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof are explained in detail as follows.
The term "lower" as used in this specification means, unless otherwise indicated, any number of carbon atoms between 1 and 6, inclusive.
Suitable "alkyl" means straight or branched saturated aliphatic hydrocarbon residue and may include lower alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, neopentyl, hexyl, and the like.
Suitable "alkenyl" means straight or branched unsaturated aliphatic hydrocarbon residue having one double bond and may include lower alkenyl such as vinyl, propenyl, butenyl, metylpropenyl, pentenyl, hexenyl, and the like.
Suitable "aryl" may include phenyl, tolyl, xylyl, cumenyl mesityl, naphthyl, and the like.
Suitable examples of the protective group in the "protected hydroxyl group" may include:
1-(lower alkylthio)(lower)alkyl groups such as lower alkylthiomethyl groups (e.g. methylthiomethyl, ethylthiomethyl, propylthiomethyl, isopropylthiomethyl, butylthiomethyl, isobutylthiomethyl, hexylthiomethyl, etc.), more desirably
C1 -C4 alkylthiomethyl groups, and most desirably methylthiomethyl; tri-substitueted silyl groups such as tri(lower)-alkylsilyl groups (e.g. trimethylsilyl, triethylsilyl, tributylsilyl, tert-butyl-dimethylsilyl, tri-tert-butylsilyl, etc.); lower alkyl-diarylsilyl groups (e.g. methyldiphenylsilyl, ethyldiphenylsilyl, propyldiphenylsilyl, tert-butyldiphenylsilyl, etc.), more desirably tri(C1 -C4)alkylsilyl and C1 -C4 alkyldiphenylsilyl groups and most desirably tert-butyldimethylsilyl and tert-butyldiphenylsilyl; and acyl groups such as aliphatic acyl groups, aromatic acyl groups and aliphatic acyl groups substituted by aromatic groups, which are derived from carboxylic acids, sulfonic acids or carbamic acids.
The aliphatic acyl group may includes lower alkanoyl groups which may optionally have one or more suitable substituents such as carboxy (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, carboxyacetyl, carboxypropionyl, carboxybutyryl, carboxyhexanoyl, etc.), cyclo(lower)alkoxy - (lower)alkanoyl groups which may optionally have one or more appropriate substituents such as lower alkyl (e.g. cyclopropyloxyacetyl, cyclobutyloxypropionyl, cycloheptyloxybutyryl, menthyloxyacetyl, menthyloxypropionyl, menthyloxybutyryl, menthyloxypentanoyl, menthyloxyhexanoyl, etc.), camphorsulfonyl, lower alkylcarbamoyl groups having one or more suitable substituents such as carboxy or protected carboxy, for example carboxy(lower)alkylcarbamoyl groups(e.g. carboxymethylcarbamoyl, carboxyethylcarbamoyl, carboxypropylcarbamoyl, carboxybutylcarbamoyl, carboxypentylcarbamoyl, carboxyhexylcarbamoyl, etc. , protected caroxy(lower)alkylcarbamoyl groups suc as tri(lower)alkylsilyl(lower)alkoxycarbonyl(lower)alkylcarbamoyl groups (e.g. trimethylsilylmethoxycarbonylethylcarbamoyl, trimethylsilylethoxycarbonylpropylcarbamoyl, triethylsilylethoxycarbonylpropylcarbamoyl, tert-butyldimethylsilylethoxycarbonylpropylcarbamoyl, trimethylsilylpropoxycarbonylbutylcarbamoyl, etc.) and so on.
The aromatic acyl group may include aroyl groups which may optionally have one or more suitable substituents such as nitro (e.g. benzoyl, toluoyl, xyloyl, naphthoyl, nitrobenzoyl, dinitrobenzoyl, nitronaphthoyl, etc., arenesulfonyl groups which may optionally have one or more suitable substituent(s) such as halogen (e.g. benzenesulfonyl, toluenesulfonyl, xylenesulfonyl, naphthalenesulfonyl, fluorobenzenesulfonyl, chlorobenzenesulfonyl, bromobenzenesulfonyl, iodobenzenesulfonyl, etc.), and so on.
The aromatic group-substituted aliphatic acyl groups may include ar(lower)alkanoyl groups which may optionally have one or more suitable substituent(s) such as lower arkoxy and trihalo(lower)alkyl (e.g. phenylacetyl, phenylpropionyl, phenylbutyryl, 2-trifluoromethyl-2-methoxy-2-phenylacetyl, 2-ethyl-2-trifluoromethyl-2-phenylacetyl, 2-trifluoromethyl-2-propoxy-2-phenylacetyl, etc. , and so on.
Among the above-mentioned acyl groups, the more desirable acyl groups are C1 -C4 alkanoyl groups which may optionally be substituted by carboxy, cyclo(C5 -C6)alkyloxy(C1 -C4)alkanoyl groups having two (C1 -C4)alkyl groups in the cycloalkyl moiety, camphorsulfonyl, carboxy(C1 -C4)alkylcarbamoyl groups, tri(C1 -C4) alkylsilyl(C1 -C4)alkoxycarbonyl(C1 -C4)alkylcarbamoyl groups, benzoyl which may have one or two nitro groups, halogen-substituted benzenesulfonyl groups, phenyl(C1 -C4)alkanoyl groups having C1 -C4 alkoxy and trihalo(C1 -C4)alkyl groups. Of these groups, the most desirable are acetyl, carboxypropionyl, menthyloxyacetyl, camphorsulfonyl, benzoyl, nitrobenzoyl, dinitrobenzoyl, iodobenzenesulfonyl and 2-trifluoromethyl-2-methoxy-2-phenylacetyl.
Suitable "5- or 6-membered N-, S- or O- containing heterocyclic ring" may include pyrrolyl, tetrahydrofuryl, and the like.
The pharmaceutically acceptable salt of compound (I) is a nontoxic salt, which may be the corresponding salt with an inorganic or organic base such as alkali metal salts (e.g. sodium salt, potassium salt, etc.), ammonium salt and amine salts (e.g. triethyamine salt, N-benzyl-N-methylamine salt, etc.), and so on.
With regard to the compound I of the present invention, it is to be noted that there may be one or more than one conformers on stereoisomers such as optically or geometrically isomeric pairs due to the presence of one or more than one assymetric carbon atom or double bond, and these are included within a scope of the compound (I) of the present invention.
It will hereinafter be described in detail how the present invention has completed, especially relating to the important point of the present invention i.e., the reason why a mixture of surface active agent and nonaqueous solvent is selected in this invention.
A liquidous pharmaceutical containing the compound (I) should be offered as a stable liquid as it is for the purpose of administrating to human body and transferring the effective amount of the ingredient compound to human body. Further on considering a special use such as intravenous injection that is the main object of the present invention, should be offered a whole clear liquidous pharmaceutical which can maintain the clearity under long term storage.
From the above point of view, the inventors of the present invention studied, at first, the solubility of the compound (I) in water. As a test compound, the inventors selected the following compound as a free form which has an excellent immunosuprressive activity and is called FK 506 hereafter.
______________________________________R.sup.1, R.sup.2, R.sup.8, R.sup.23 = hydrogen R.sup.7, R.sup.9 = hydroxyR.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.22 =methyl R.sup.10 = allylR.sup.20 = R.sup.20 a, H (R.sup.20 a = methoxy) X, Y = oxygenR.sup.21 = R.sup.21 a, H (R.sup.21 a = hydroxy) n = 2R.sup.3, R.sup.4 = form a second bond between the vicinal carbon atomsto which they are attachedR.sup.5, R.sup.6 = form a second bond between the vicinal carbon atomsto which they are attached______________________________________
The solubility of FK 506 in water is at most 3 μg/ml under ambient temperature. Accordingly, it is decided to add a surface active agent in order to increase the solubility of FK 506 in water to the level where the clinically effective amount of FK 506 is dissloved. Table 1 shows the solubility of FK 506 under the different condition e.g., the kind and the concentration of a surface active agent and temperature. As a surface active agent, a castor oil-surface active agent i.e., HCO-10, HCO-40, HCO-60 (trademark, prepared by Nikko Chemicals, respectively) are selected for examination.
It is conjectured from the result shown in Table 1 that the concentration of the surface active agent should be controlled at 1.43w/v% [about 150 mg of the surface active agent against 1 mg of FK506] to dissolve 0.1 mg of FK 506 in 1 ml of water, calculating based on the result that 0.035 mg of FK 506 is dissolved in 1 ml of 0.5w/v% HCO-60 aqueous solution at 20° C. Accordingly, if it is desired to prepare 5 mg/ml aqueous solution FK 506, the concentration of the surface active agent is estimated to come up to 87w/v% from the calculation based on the result of HCO-60, 20w/v%, 20° C . Such tolerably high concentration of surface active agent in aqueous solution should not be realized in practice of clinical field.
TABLE 1______________________________________ Kind of surface active agent and solubilityConcentration of FK506 (mg/ml)of surface Mixture of HCO-60active agent HCO-40 HCO-60 and HCO-10 (4:1)(w/v %) 20° C. 20° C. 30° C. 20° C. 30° C.______________________________________0.1 -- 0.005 -- -- --0.3 -- 0.019 -- -- --0.5 -- 0.035 -- -- --5 0.40 0.28 0.29 0.26 0.2710 0.78 0.61 0.57 0.56 0.5620 1.52 1.15 1.14 1.13 1.14______________________________________ HCO-60: Polyoxyethylenehydrogenated Castor Oil 60 HCO40: Polyoxyethylenehydrogenated Castor Oil 40 HCO10: Polyoxyethylenehydrogenated Castor Oil 10
Table 2 shows a remaining percentage of FK 506 in aqueous solution wherein FK 506 is dissolved in water in the presence of large amount of surface active agent. From this table, it is found that the stability for long period storage is not expectable in the above prescription.
TABLE 2______________________________________ Remaining percentage of FK 506 (%) (prescription) FK 506 0.5 mgStorage HCO-60 100 mgconditions phosphoric acid buffer (pH 6) 1 ml______________________________________Initial 100.0After 3 days 52.7(at 40° C.)After 3 days 42.2(at 80° C.)______________________________________
From the results of the above experiment, it is recognized that the use of surface active agent is not profitable means for the purpose of dissolving the compound (I), for example FK 506, in water.
Table 3 shows solubility of FK 506 in several kinds of nonaqueous solvent such as PEG (polyethylene glycol) 400, ethanol and propylene glycol. From the consideration of the illustrated data, it is found that PK 506 is dissolved in the experimented solvent at the concentration of more than 40 mg/ml.
TABLE 3______________________________________ SolubilitySolvent (at ambient temperature)______________________________________Ethanol >300PEG 400 >40Propylene glycol >40(mg/ml)______________________________________
Nonaqueous solvent is, at the time of administrating into the human vascular tract, usually diluted with aqueous solvent such as physiological saline, since nonaqueous solvent has hemolysis action. Therefore, the inventors of the present invention diluted the experimental solution by using nonaqueous solution (1 ml) described in the following prescriptions 1 & 2 with physiological saline (100 ml), and it was found that the nonaqeuous solution became turbid at once and fine crystal of FK 506 was precipitated in a mixed medium.
______________________________________(Prescription 1)FK 506 10 mgEthanol to 1 ml(Prescription 2)FK 506 10 mgPropylene glycol to 1 ml______________________________________
Standing on the above result, the inventors of the present invention have then studied on combination use of nonaqueous solvent and surface active agent.
The experimental solution (1 ml) of the following prescription 3 consisting of FK 506, surface active agent and nonaqueous solvent was diluted with physiological saline (100 ml) to find that the clear appearance of prescription was kept unchange.
______________________________________(Prescription 3)______________________________________ FK 506 10 mg HCO-60 100 mg Ethanol to 1 ml______________________________________
Then several prescriptions of clear solution were further prepared altering the concentration of FK 506, the kind and the concentration of surface active agent, and were tested how change the clearity of the solution and whether separate out the crystal or not under the several condition of different degree of dilution. The results thereof are shown in Table 4.
TABLE 4__________________________________________________________________________Concentration Dilution times Period till solution becomes turbid to crystallize FK506 (in days)of with Kind of surface active agent/Ratio of ethanol to surface active agentFK 506 physiological HCO-60 Cremophor ® EL HCO-40(mg/ml) saline 35/65 60/40 80/20 35/65 80/20 40/60 80/20__________________________________________________________________________ 5 2 ≧7 ≧7 ≧7 ≧7 ≧7 ≧7 ≧7 100 ≧7 ≧7 ≧7 ≧7 ≧7 ≧7 ≧710 2 ≧7 ≧7 ≧7 ≧7 ≧7 ≧7 ≧7 100 ≧7 ≧7 ≧7 ≧7 ≧7 ≧7 ≧725 2 ≧7 ≧7 ≧7 ≧7 ≧7 ≧7 ≧7 100 ≧7 ≧1 ≧7 ≧7 ≧1 ≧7 ≧150 2 ≧7 ≧7 ≧7 ≧7 ≧1 ≧7 ≧1__________________________________________________________________________ Cremophor ® EL: trademark, prepared by BASF (Polyoxyethykene Castor Oil 35)
It is concluded from the result illustrated in Table 4 that a clear pharmaceutical solution which does not cause Precipitation of the compound (I) on diluting with physiological saline can be prepared by controlling the ratio of the compound(I), surface active agent and nonaqueous solvent according to the kind of surface active agent under the condition that the concentration of the compound (I) is less than 50 mg/ml.
Lastly it is tested the remaining percentage of FK 506 after storage in nonaqueous solvent containing both FK 506 and surface active agent. In the test solution, the concentration of FK 506 is adjusted to 5 mg/ml, and, for comparative a nonaqueous solution which contain only FK 506 is prepared. The experimental result is shown in Table 5.
TABLE 5______________________________________ Remaining percentage of FK 506(%) (prescription) FK 506 5 mgStorage HCO-60 400 mgconditions ethanol to 1 ml______________________________________Initial 100.080° C. 1 day 95.2 3 day 90.4 5 day 86.4 10 day 78.6 17 day 68.060° C. 5 day 96.4 10 day 95.1 17 day 92.4 1 month 88.040° C. 1 month 96.7 3 month 96.6 18 month 84.6______________________________________
It is concluded from the result shown in table 5 that HCO-60 is the most preferable surface active agent in the view point of storage stability.
As considered from the above experiments, the compound (I) such as FK 506 has quite poor solubility in water and this is not so improved even in the presence of surface active agent, and the storage stability especially at ambient temperature is quite inferior excepting that only frozen one can stand for some period of time.
In the mean time, it is found that the compound (I) is well dissolved in nonaqueous solvent. However it causes precipitation of the compound (I) on diluting with physiological saline to diminishing hemolysis action of nonaqueous solvent. Occurence of precipitation makes it impossible to use in the clinical field.
Under the condition of cooperative use of nonaqueous solvent and surface active agent, it is noted that the compound (I) is well dissolved and there is no problem after long pereiod storage, and further it does not happen to give any Precipitate at the time of diluting with physiological saline.
The kind of nonaqueous solvent is not limited in the present invention, and any nonaqueous solvent may be used as much as it can dissolve the effective amount of the compound (I) and it may be acceptable in clinical use. The nonaqueous solvent may be used either alone or as a mixture thereof. Suitable examples thereof include ethanol, propylene glycol, glycerin, Polyethylene glycol (e.g., PEG 400, PEG 300, PEG 200, etc.), or the mixture thereof from a view point of solubility and viscosity, etc. and most preferable one is ethanol. The representative examples of the surface active agent include, from a view point of storage stability for long term, a castor oil-surface active agents, and more preferable one is HCO (polyoxyethylene hardened oil)-surface active agents, and most preferable one is HCO-60, HCO-50 and the like. In addition to the above exemplified surface active agents, polyoxyethylene sorbitane fatty acid ester derivative (e.g., Polysorbate 80, etc.,), glycerine fatty acid ester derivative (e.g., glycerine monocaprylate, etc.), polyethylene glycol fatty acid ester derivative (e.g., polyoxyethylene 40 monostearate, etc.), and the like may also be used.
The concentration of the compound (I) is determined from the judgement including the kind and the concentration of nonaqueous solvent and surface active agent, the composition ratio thereof, the stability after being diluted with physiological saline, etc. and storage stability. The suitable range of thus determined concentration is usually in the range of 0.1˜50 mg/ml and more preferably 1˜20 mg/ml.
As for the amount of surface active agent, it is noted to be less than the calculated estimation. From the experimental calculation based on the result illustrated in Table 1, about 150 mg of the surface active agent may be necessary to obtain a saturated aqueous solution containing 1 mg of the compound (I) as stated above. However in the present invention the compound (I) is dissolved in a mixed solution of nonaqueous solvent--surface active agent--water to form stable supersaturation state, and therefore the necessary amount ofsurface active agent becomes less than the calculated one. These specific action, i.e., the low precipitating speed of thecrystalline from the supersaturated solution, is based on the characteristic property of the compound (I). The range of the ratio of surface active agent to the compound (I) is preferably 1˜100 mg/1 mg. and more preferably 30˜60 mg/1 mg to prevent the occurence of precipitation at the time of diluting for clinical use.
The pharmaceutical solution of the present invention may further contain, if necessary, other agent such as stabilizing agent, anodyne, and the like.
The pharmaceutical solution of the present invention is stable during long term storage and does not occur the precipitation of crystalline at the time of dilution. Therefore, this is applicable to various kind of medicine form such as intravenous injection, dropping lotion in the eye, dropping lotion in the nose, intraenteric injection, percutaneous liniment, local scattering agent, oral administration agent (e.g., syrup, etc.), and the like.
Following prescriptions are shown only for the purpose of the explanation of this invention.
______________________________________Prescription 1______________________________________ FK 506 10 mg HCO-60 400 mg Ethanol to 1 ml______________________________________
The solution comprising the ingredients stated above is prepared by dissolving the FK 506 and HCO-60 in ethanol by a conventional manner.
The following solutions are also prepared a similar manner of the Prescription 1.
______________________________________Prescription 2FK 506 5 mgHCO-40 200 mgPEG 400 to 1 mlPrescription 3FK 506 2 mgPolysorbate 80 50 mgPropylene glycol to 1 mlPrescription 4FK 506 2 mgPolysorbate 80 10 mgGlycerine 0.5 mlEthanol to 1 mlPrescription 5FK 506 2 mgHCO-60 20 mgPropylene glycol to 1 mlPrescription 6FK 506 1 mgPolyoxyethylene (40) mono stearate 20 mgPropylene glycol to 1 mlPrescription 7FK 506 10 mgHCO-60 400 mgEthanol to 1 mlPrescription 8FK 506 5 mgHCO-60 400 mgEthanol to 1 mlPrescription 9FK 506 25 mgHCO-60 400 mgEthanol to 1 mlPrescription 10FK 506 2 mgHCO-60 10 mgGlycerine 0.5 mlEthanol to 1 ml______________________________________
Effect of the Invention
Thus obtained nonaqueous pharmaceutical solution containing the compound (I) is stable during long term storage and does not occur any precipitation at the time of diluting with physiological saline, glucose solution for injection, water, fruit juice, milk, or the like for clinical use. Accordingly, the pharmaceutical solution of the present invention is applicable to various kind of medicine form such as intravenous injection, oral administration agent and the like, which could contribute the compound (I) in clinical field wherein its immunosuppressive activity is intensely desired. Paticularly, the most preferable medicine form of the present nonaqueous pharmaceutical solution is the one for intravenous injection by diluting with the physiological saline.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3997590 *||Jun 28, 1973||Dec 14, 1976||B.D.H. Pharmaceuticals Ltd.||Keto-esters|
|US4082780 *||Nov 22, 1976||Apr 4, 1978||Takeda Chemical Industries, Ltd.||Estradiol derivatives|
|US4894366 *||Nov 20, 1985||Jan 16, 1990||Fujisawa Pharmaceutical Company, Ltd.||Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same|
|US5023262 *||Aug 14, 1990||Jun 11, 1991||American Home Products Corporation||Hydrogenated rapamycin derivatives|
|US5064835 *||Mar 1, 1990||Nov 12, 1991||Merck & Co., Inc.||Hydroxymacrolide derivatives having immunosuppressive activity|
|EP0323042A1 *||Dec 2, 1988||Jul 5, 1989||FISONS plc||Process to macrocyclic compounds|
|JPS61148181A *||Title not available|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5496564 *||Aug 26, 1994||Mar 5, 1996||Fujisawa Pharmaceutical Co., Ltd.||Suspendible composition and process for preparing the same|
|US5514685 *||May 15, 1995||May 7, 1996||Sandoz Ltd.||Heteroatom-containing tricyclic compounds|
|US5601844 *||Nov 11, 1993||Feb 11, 1997||Fujisawa Pharmaceutical Co., Ltd.||Sustained release medicinal preparation|
|US5817333 *||May 22, 1995||Oct 6, 1998||Fujisawa Pharmaceutical Co., Ltd.||Liposome preparation containing a tricyclic compound|
|US5939427 *||Jan 5, 1998||Aug 17, 1999||Fujisawa Pharmaceutical Co., Ltd.||Lotion for FK 506|
|US5955469 *||Jul 25, 1994||Sep 21, 1999||Fujisawa Pharmaceutical Co., Ltd.||Pharmaceutical composition|
|US6486124||Oct 17, 2001||Nov 26, 2002||Novartis Ag||Cyclosporin compositions and process therefor|
|US6492325||Apr 15, 1999||Dec 10, 2002||Boys Town National Research Hospital||Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease|
|US6599535||Jul 12, 2002||Jul 29, 2003||Novartis Ag||Pharmaceutical compositions|
|US6951841 *||Dec 15, 2000||Oct 4, 2005||Novartis Ag||Pharmaceutical compositions of macrolides or cyclosporine with a polyethoxylated saturated hydroxy-fatty acid|
|US6956043||Jun 4, 2003||Oct 18, 2005||Novartis Ag||Pharmaceutical compositions comprising 33-epi-chloro-33-desoxy-ascomycin solid dispersions|
|US7642338||Jun 20, 2006||Jan 5, 2010||Siemens Healthcare Diagnostics Inc.||Tacrolimus standard and methods of using same|
|US8153594||Nov 18, 2009||Apr 10, 2012||Siemens Healthcare Diagnostics Inc.||Tacrolimus standard and methods of using same|
|US9044391||Jan 10, 2008||Jun 2, 2015||Board Of Regents, The University Of Texas System||Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery|
|US9060928 *||Apr 2, 2010||Jun 23, 2015||Fuzhou Harvester Pharmaceutical R&D Co., Ltd.||Tacrolimus injection preparation|
|US9168246 *||Jun 27, 2014||Oct 27, 2015||Veloxis Pharmaceutical A/S||Regimen for suppressing organ rejection|
|US9775834||Sep 28, 2015||Oct 3, 2017||Veloxis Pharmaceuticals A/S||Regimen for supressing organ rejection|
|US20020094956 *||Mar 12, 2002||Jul 18, 2002||Boys Town National Research Hospital||Use of alpha1beta1 integrin receptor inhibitors and TGF-beta1 inhibitors in the treatment of kidney disease|
|US20030211160 *||Jun 4, 2003||Nov 13, 2003||Patrice Guitard||Pharmaceutical compositions|
|US20060115533 *||Oct 21, 2005||Jun 1, 2006||Patrice Guitard||Pharmaceutical compositions|
|US20060178514 *||Dec 28, 2005||Aug 10, 2006||Anima Baruah||Novel benzylamine derivatives as CETP inhibitors|
|US20070292891 *||Jun 20, 2006||Dec 20, 2007||Wei Tie Q||Tacrolimus standard and methods of using same|
|US20080125456 *||Nov 11, 2005||May 29, 2008||Chong Kun Dang Pharmaceutical Corporation||Injection of Tacrolimus|
|US20100062459 *||Nov 18, 2009||Mar 11, 2010||Siemens Healthcare Diagnostics Inc.||Tacrolimus Standard and Methods of Using Same|
|US20100183721 *||Jan 10, 2008||Jul 22, 2010||Board Of Regents, The University Of Texas System||Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery|
|US20100316724 *||May 11, 2010||Dec 16, 2010||Innovata Limited||Composition|
|US20120059027 *||Apr 2, 2010||Mar 8, 2012||Fuzhou Harvester Pharmaceutical R&D Co., Ltd.||Tacrolimus injection preparation|
|US20150004154 *||Jun 27, 2014||Jan 1, 2015||Veloxis Pharmaceuticals A/S||Regimen for suppressing organ rejection|
|EP2037944A2 *||Jun 18, 2007||Mar 25, 2009||Siemens Healthcare Diagnostics Inc.||Tacrolimus standard and methods of using same|
|EP2037944A4 *||Jun 18, 2007||Oct 13, 2010||Siemens Healthcare Diagnostics||Tacrolimus standard and methods of using same|
|WO2004062692A1 *||Jan 12, 2004||Jul 29, 2004||Solvay Pharmaceuticals B.V.||Formulation of poorly water-soluble active substances|
|WO2006052098A1 *||Nov 11, 2005||May 18, 2006||Chong Kun Dang Pharmaceutical Corp.||The injection of tacrolimus|
|U.S. Classification||514/291, 514/970, 514/943, 514/789, 514/786, 514/284, 514/975|
|International Classification||A61K31/445, A61K47/26, A61K31/40, A61K9/00, A61K47/10, A61K47/44, A61K47/14, A61K31/55|
|Cooperative Classification||Y10S514/943, Y10S514/97, Y10S514/975, A61K31/55, A61K31/445, A61K47/26, A61K31/40, A61K47/14, A61K47/10, A61K47/44, A61K9/0019|
|European Classification||A61K31/40, A61K31/55, A61K47/10, A61K9/00M5, A61K31/445, A61K47/44, A61K47/26, A61K47/14|
|Aug 13, 1993||AS||Assignment|
Owner name: FUJISAWA PHARMACEUTICAL CO., LTD., JAPAN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKANISHI, SHIGEO;YAMANAKA, IWAO;REEL/FRAME:006668/0268;SIGNING DATES FROM 19930721 TO 19930727
|Mar 14, 1995||CC||Certificate of correction|
|Apr 29, 1997||FPAY||Fee payment|
Year of fee payment: 4
|Apr 19, 2001||FPAY||Fee payment|
Year of fee payment: 8
|Apr 13, 2005||FPAY||Fee payment|
Year of fee payment: 12
|Dec 19, 2005||AS||Assignment|
Owner name: ASTELLAS PHARMA INC. (FORMERLY YAMANOUCHI PHARMACE
Free format text: MERGER/CHANGE OF NAME;ASSIGNOR:FUJISAWA PHARMACEUTICAL CO., LTD.;REEL/FRAME:016902/0759
Effective date: 20050401